KatCarney

19 Sep 2001 05:30
(kat note: eulexin is rx'd by "some" doctors to control pcos'ers excess hair. It is a controversial drug for women, however, some say it works well. Do a "search" in this forum for more articles (there are many). ALso visit the article database above)


Barr Receives Approval for Generic Eulexin(R) Tablets

Distributed by PRNewswire, POMONA, N.Y. Sept. 18

Barr Laboratories, Inc. (NYSE: BRL) today announced that it has received approval from the U.S. Food & Drug Administration (FDA) for Flutamide
Capsules, USP 125 mg the generic equivalent of Schering Corporation's Eulexin(R) capsules. The approval of the Company's product follows the
expiration of a patent granted to Schering Corporation for its Eulexin product.

"The Company is pleased to add Flutamide to our portfolio of oncology products and expects to launch the product immediately," said Bruce L.
Downey, Barr's Chairman and CEO. "This most recent approval demonstrates our on-going commitment to developing and marketing generic and
proprietary pharmaceutical products in the oncology category that includes our CyPat(TM) product used to treat symptoms associated with prostate
cancer therapy that is currently in Phase III clinical studies."

Eulexin is indicated for use in combination with LHRH agonists for the management of locally confined Stage B2-C and D2 metastatic carcinoma of
the prostate. Current annual sales are approximately $60 million.

Barr recently announced that the Company has entered into a merger agreement with Duramed Pharmaceuticals, Inc. (NASDAQ: DRMD) , a
developer, manufacturer and marketer of prescription drug products, focusing on women's health and the hormone replacement therapy markets. The
transaction is subject to customary approvals and other conditions, and is expected to close late this fall.

Barr Laboratories, Inc. is a specialty pharmaceutical company engaged in the development, manufacture and marketing of generic and proprietary
pharmaceuticals.

Safe Harbor Statement: To the extent that any statements made in this release contain information that is not historical, these statements are
essentially forward-looking. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual
results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include: the timing
and outcome of legal proceedings; the difficulty of predicting the timing of U.S. Food and Drug Administration ("FDA") approvals; the difficulty in
predicting the timing and outcome of FDA decisions on patent challenges; market and customer acceptance and demand for new pharmaceutical
products; ability to market proprietary products; the impact of competitive products and pricing; timing and success of product development and
launch; availability of raw materials; the regulatory environment; fluctuations in operating results; and, other risks detailed from time-to-time in the
Company's filings with the Securities and Exchange Commission. Forward-looking statements can be identified by the use of words such as
"expects," "plans," "will," "believes," "estimates," "intends," "may" and other words of similar meaning. Should known or unknown risks or
uncertainties materialize, or should our assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company
undertakes no obligation to publicly update any forward-looking statements.

MAKE YOUR OPINION COUNT - Click Here

http://tbutton.prnewswire.com/prn/11690X93936445

Company News On-Call: http://www.prnewswire.com/comp/089750.html

Data source:Barr Laboratories, Inc.

Contact: Carol A. Cox of Barr Laboratories, Inc., +1-845-348-6808, ccox@barrlabs.com

Web site: http://www.barrlabs.com/



More information from Barr Laboratories, Inc.

__________________